Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153013 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL24835469 | 0.84 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL6742480 | 0.78 | ALOX15 (0.48) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL14094661 | 0.78 | CYP19A1 (0.46) | ALDH1A1SMN1; SMN2LMNAMAPTALPG | |
| SCHEMBL15858815 | 0.78 | TSHR (0.56) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL13153017 | 0.78 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL7823977 | 0.78 | KMT2A (0.53) | ALDH1A1SMN1; SMN2LMNAHTTMAPT | |
| SCHEMBL23169316 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL9969438 | 0.77 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL20718709 | 0.77 | ESR1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | ALDH1A1 4585/4885SMN1; SMN2 2724/4885LMNA 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.